| [1] | Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction:a systematic review of randomized clinical trials[J]. Eur Heart J, 20089,30(4):469-477. |
| [2] | Sinclair M, Grossmann M, Gow PJ, et al. Testosterone in men with advanced liver disease:Abnormalities and implications[J]. J Gastroenterol Hepatol, 2015,30(2),:244-251. |
| [3] | Le HH, El-Khatib C, Mombled M, et al. Impact of aldosterone antagonists on sudden cardiac death prevention in heart failure and post-myocardial infarction patients:A systematic review and Meta-analysis of randomized controlled trials[J].PloS one, 2016,11(2):e0145958. |
| [4] | 白厚喜,林鹂鸣,徐恩斌,等.男性肝硬化患者乳房发育45例分析[J]. 国际消化病杂志, 2011,31(3):185-186. |
| [5] | Seferovic PM, Pelliccia F, ZivkovicI, et al. Mineralocorticoid receptor antagonists, a class beyond spironolactone-Focus on the special pharmacologic properties of eplerenone[J]. Int J Cardiol,2015,200(11):3-7. |
| [6] | 方红贤. 螺内酯治疗皮肤病578例分析[J]. 同济大学学报(医学版), 2001,22(6):49,60. |
| [7] | Batterink J, Stabler SN, Tejani AM, et al. Spironolactone for hypertension[J]. Cochrance Databse Syst Rev, 2010,8:CD008169. |
| [8] | Becker,ML, Visser LE, Van G elder T, et al. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged > or=55 years[J]. Drugs Aging, 2008,25(2):145-152. |
| [9] | 张丹, 段思栋, 小剂量螺内酯治疗冠心病慢性心力衰竭的疗效及安全性分析[J]. 中国初级卫生保健, 2014,28(6):112-114. |
| [10] | 陈富超,方宝霞,李开俊,等.药源性溢乳和男性乳房发育症系列病例文献分析[J].药物流行病学杂志,2006,15(6):348-349. |
| [11] | Pelliccia F, Patti G Rosano G, et al. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension:Systematic review and meta-analysis[J]. Int J Cardiol, 2014,177(1):219-228. |
| [12] | 陆人杰, 朱珊梅, 唐风雷. 1例螺内酯致男性乳房发育症的病例分析[J].医学信息, 2013,28:678. |